English

REATA PHARMACEUTICALS INC

EDGAR

RETA Quarterly report (10-Q) · filed 2023-08-08

47 filing records in this dataset, filed from 2016-01-04 to 2023-08-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

22.7 million USD

2023 Q2 · USD

Exact inputs and evidence

Revenue: 22746000 USD Source

Net margin

848.49%

2023 Q2 · %

Exact inputs and evidence

Net Income: 192998000 USD Source
Revenue: 22746000 USD Source

Operating cash flow

-69.9 million USD

2023 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -151377000 USD Source
Operating Cash Flow: -81449000 USD Source

Free cash flow

-70.2 million USD

2023 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -151377000 USD Source
Operating Cash Flow: -81449000 USD Source
Capital Expenditure: 415000 USD Source
Capital Expenditure: 141000 USD Source

Cash and cash equivalents: 48.8 million USD 2023-06-30 Source
Exact value

48843000 USD
Long-term debt including current maturities: 73.1 million USD 2023-06-30 Source
Exact value

73130000 USD
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

23.5 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Revenue: 540000 USD · 2022-07-01 – 2022-09-30 Source
Revenue: 2216000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 2216000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 195000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 22746000 USD · 2023-04-01 – 2023-06-30 Source

Net income

-87.6 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Net income: -79002000 USD · 2022-07-01 – 2022-09-30 Source
Net income: -311901000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -226399000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -116117000 USD · 2023-01-01 – 2023-03-31 Source
Net income: 192998000 USD · 2023-04-01 – 2023-06-30 Source

Operating cash flow

-248 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Operating cash flow: -153841000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -107307000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -204267000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -153841000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -81449000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -151377000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -81449000 USD · 2023-01-01 – 2023-03-31 Source

Capital expenditure

1.12 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Capital expenditure: 2903000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 2562000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 3270000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 2903000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 141000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 415000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 141000 USD · 2023-01-01 – 2023-03-31 Source

Free cash flow

-249 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Operating cash flow: -153841000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -107307000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -204267000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -153841000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -81449000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -151377000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -81449000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 2903000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 2562000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 3270000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 2903000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 141000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 415000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 141000 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-08-08.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2022-12-31
operating income: No compatible figures in this window
Net income: 9 of 11 periods available· newest 2022-12-31
Operating cash flow: 9 of 11 periods available· newest 2022-12-31
Capital expenditure: 9 of 11 periods available· newest 2022-12-31
Total assets: 9 of 11 periods available· newest 2022-12-31
liabilities: No compatible figures in this window
Current assets: 9 of 11 periods available· newest 2022-12-31
Current liabilities: 9 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2022-12-31
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-80.7%

Prior period

USD 11.49 million

2021-01-01 – 2021-12-31
Current period

USD 2.22 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

2216000 − 11490000 = -9274000 USD

11490000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
2216000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · REATA PHARMACEUTICALS INC · 2022-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Year-over-year change in Revenue: -9274000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 2216000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3263824 Filing: 000095017023004236 Input fundies:Revenue: 11490000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3265761 Filing: 000095017023004236
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 14.52 million

Prior period

−USD 297.39 million

2021-01-01 – 2021-12-31
Current period

−USD 311.9 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-311901000 − -297386000 = -14515000 USD

-297386000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-311901000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · REATA PHARMACEUTICALS INC · 2022-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Year-over-year change in Net income: -14515000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -311901000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#4680479 Filing: 000095017023004236 Input fundies:NetIncome: -297386000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#4682735 Filing: 000095017023004236
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 31.43 million

Prior period

−USD 235.7 million

2021-01-01 – 2021-12-31
Current period

−USD 204.27 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-204267000 − -235701000 = 31434000 USD

-235701000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-204267000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · REATA PHARMACEUTICALS INC · 2022-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Year-over-year change in Operating cash flow: 31434000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -204267000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3757390 Filing: 000095017023004236 Input fundies:OperatingCashFlow: -235701000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3759594 Filing: 000095017023004236
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+146%

Prior period

USD 1.33 million

2021-01-01 – 2021-12-31
Current period

USD 3.27 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

3270000 − 1329000 = 1941000 USD

1329000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
3270000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · REATA PHARMACEUTICALS INC · 2022-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Year-over-year change in Capital expenditure: 1941000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3270000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3768611 Filing: 000095017023004236 Input fundies:CapitalExpenditure: 1329000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3770804 Filing: 000095017023004236
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 2.22 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income −USD 311.9 million −14,075% of revenue

Cash

Operating cash flow −USD 204.27 million −9,218% of revenue
Capital expenditure USD 3.27 million 148% of revenue
Free cash flow Derived −USD 207.54 million −9,365% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Not shown: operating income or net income is not reported.
2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	51954000	Unavailable	Unavailable	Unavailable	689000	-88813000 Derived	Source 2014-01-01 – 2014-12-31: 51954000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: 689000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -88630000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 183000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	50319000	Unavailable	Unavailable	Unavailable	-1450000	-44892000 Derived	Source 2015-01-01 – 2015-12-31: 50319000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -1450000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -44620000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 272000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	49856000	Unavailable	Unavailable	Unavailable	-6227000	-19599000 Derived	Source 2016-01-01 – 2016-12-31: 49856000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -6227000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -19259000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 340000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	48058000	Unavailable	Unavailable	Unavailable	-47671000	-83600000 Derived	Source 2017-01-01 – 2017-12-31: 48058000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -47671000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -83256000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 344000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	53589000	Unavailable	Unavailable	Unavailable	-80546000	-84462000 Derived	Source 2018-01-01 – 2018-12-31: 53589000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -80546000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -83783000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 679000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	26517000	Unavailable	Unavailable	Unavailable	-290170000	-253824000 Derived	Source 2019-01-01 – 2019-12-31: 26517000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -290170000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -251151000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2673000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	9019000	Unavailable	Unavailable	Unavailable	-247752000	-323267000 Derived	Source 2020-01-01 – 2020-12-31: 9019000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -247752000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -322340000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 927000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	11490000	Unavailable	Unavailable	Unavailable	-297386000	-237030000 Derived	Source 2021-01-01 – 2021-12-31: 11490000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -297386000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -235701000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1329000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	2216000	Unavailable	Unavailable	Unavailable	-311901000	-207537000 Derived	Source 2022-01-01 – 2022-12-31: 2216000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -311901000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -204267000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 3270000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2.2M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	51954000	Revenue: 51954000 Open source
20152015-12-31	Revenue	50319000	Revenue: 50319000 Open source
20162016-12-31	Revenue	49856000	Revenue: 49856000 Open source
20172017-12-31	Revenue	48058000	Revenue: 48058000 Open source
20182018-12-31	Revenue	53589000	Revenue: 53589000 Open source
20192019-12-31	Revenue	26517000	Revenue: 26517000 Open source
20202020-12-31	Revenue	9019000	Revenue: 9019000 Open source
20212021-12-31	Revenue	11490000	Revenue: 11490000 Open source
20222022-12-31	Revenue	2216000	Revenue: 2216000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-80.7% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 51954000 Open source
20152015-12-31	Year over year	-3.1%	Revenue: 50319000 Open source Revenue: 51954000 Open source
20162016-12-31	Year over year	-0.9%	Revenue: 49856000 Open source Revenue: 50319000 Open source
20172017-12-31	Year over year	-3.6%	Revenue: 48058000 Open source Revenue: 49856000 Open source
20182018-12-31	Year over year	11.5%	Revenue: 53589000 Open source Revenue: 48058000 Open source
20192019-12-31	Year over year	-50.5%	Revenue: 26517000 Open source Revenue: 53589000 Open source
20202020-12-31	Year over year	-66%	Revenue: 9019000 Open source Revenue: 26517000 Open source
20212021-12-31	Year over year	27.4%	Revenue: 11490000 Open source Revenue: 9019000 Open source
20222022-12-31	Year over year	-80.7%	Revenue: 2216000 Open source Revenue: 11490000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Net margin -14,075% 2022

Free cash flow margin -9,365.4% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2014-12-31	Operating margin	Not reported	Revenue: 51954000 Open source
2015-12-31	Operating margin	Not reported	Revenue: 50319000 Open source
2016-12-31	Operating margin	Not reported	Revenue: 49856000 Open source
2017-12-31	Operating margin	Not reported	Revenue: 48058000 Open source
2018-12-31	Operating margin	Not reported	Revenue: 53589000 Open source
2019-12-31	Operating margin	Not reported	Revenue: 26517000 Open source
2020-12-31	Operating margin	Not reported	Revenue: 9019000 Open source
2021-12-31	Operating margin	Not reported	Revenue: 11490000 Open source
2022-12-31	Operating margin	Not reported	Revenue: 2216000 Open source
20142014-12-31	Net margin	1.3%	Net Income: 689000 Open source Revenue: 51954000 Open source
20152015-12-31	Net margin	-2.9%	Net Income: -1450000 Open source Revenue: 50319000 Open source
20162016-12-31	Net margin	-12.5%	Net Income: -6227000 Open source Revenue: 49856000 Open source
20172017-12-31	Net margin	-99.2%	Net Income: -47671000 Open source Revenue: 48058000 Open source
20182018-12-31	Net margin	-150.3%	Net Income: -80546000 Open source Revenue: 53589000 Open source
20192019-12-31	Net margin	-1,094.3%	Net Income: -290170000 Open source Revenue: 26517000 Open source
20202020-12-31	Net margin	-2,747%	Net Income: -247752000 Open source Revenue: 9019000 Open source
20212021-12-31	Net margin	-2,588.2%	Net Income: -297386000 Open source Revenue: 11490000 Open source
20222022-12-31	Net margin	-14,075%	Net Income: -311901000 Open source Revenue: 2216000 Open source
20142014-12-31	Free cash flow margin	-170.9%	Revenue: 51954000 Open source Operating Cash Flow: -88630000 Open source Capital Expenditure: 183000 Open source
20152015-12-31	Free cash flow margin	-89.2%	Revenue: 50319000 Open source Operating Cash Flow: -44620000 Open source Capital Expenditure: 272000 Open source
20162016-12-31	Free cash flow margin	-39.3%	Revenue: 49856000 Open source Operating Cash Flow: -19259000 Open source Capital Expenditure: 340000 Open source
20172017-12-31	Free cash flow margin	-174%	Revenue: 48058000 Open source Operating Cash Flow: -83256000 Open source Capital Expenditure: 344000 Open source
20182018-12-31	Free cash flow margin	-157.6%	Revenue: 53589000 Open source Operating Cash Flow: -83783000 Open source Capital Expenditure: 679000 Open source
20192019-12-31	Free cash flow margin	-957.2%	Revenue: 26517000 Open source Operating Cash Flow: -251151000 Open source Capital Expenditure: 2673000 Open source
20202020-12-31	Free cash flow margin	-3,584.3%	Revenue: 9019000 Open source Operating Cash Flow: -322340000 Open source Capital Expenditure: 927000 Open source
20212021-12-31	Free cash flow margin	-2,062.9%	Revenue: 11490000 Open source Operating Cash Flow: -235701000 Open source Capital Expenditure: 1329000 Open source
20222022-12-31	Free cash flow margin	-9,365.4%	Revenue: 2216000 Open source Operating Cash Flow: -204267000 Open source Capital Expenditure: 3270000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -204.3M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	-88630000	Operating Cash Flow: -88630000 Open source
20152015-12-31	Operating cash flow	-44620000	Operating Cash Flow: -44620000 Open source
20162016-12-31	Operating cash flow	-19259000	Operating Cash Flow: -19259000 Open source
20172017-12-31	Operating cash flow	-83256000	Operating Cash Flow: -83256000 Open source
20182018-12-31	Operating cash flow	-83783000	Operating Cash Flow: -83783000 Open source
20192019-12-31	Operating cash flow	-251151000	Operating Cash Flow: -251151000 Open source
20202020-12-31	Operating cash flow	-322340000	Operating Cash Flow: -322340000 Open source
20212021-12-31	Operating cash flow	-235701000	Operating Cash Flow: -235701000 Open source
20222022-12-31	Operating cash flow	-204267000	Operating Cash Flow: -204267000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -207.5M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	-88813000	Operating Cash Flow: -88630000 Open source Capital Expenditure: 183000 Open source
20152015-12-31	Free cash flow	-44892000	Operating Cash Flow: -44620000 Open source Capital Expenditure: 272000 Open source
20162016-12-31	Free cash flow	-19599000	Operating Cash Flow: -19259000 Open source Capital Expenditure: 340000 Open source
20172017-12-31	Free cash flow	-83600000	Operating Cash Flow: -83256000 Open source Capital Expenditure: 344000 Open source
20182018-12-31	Free cash flow	-84462000	Operating Cash Flow: -83783000 Open source Capital Expenditure: 679000 Open source
20192019-12-31	Free cash flow	-253824000	Operating Cash Flow: -251151000 Open source Capital Expenditure: 2673000 Open source
20202020-12-31	Free cash flow	-323267000	Operating Cash Flow: -322340000 Open source Capital Expenditure: 927000 Open source
20212021-12-31	Free cash flow	-237030000	Operating Cash Flow: -235701000 Open source Capital Expenditure: 1329000 Open source
20222022-12-31	Free cash flow	-207537000	Operating Cash Flow: -204267000 Open source Capital Expenditure: 3270000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2014-12-31	Liabilities / assets	Not reported	Total Assets: 125604000 Open source
2015-12-31	Liabilities / assets	Not reported	Total Assets: 78954000 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 89093000 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 135337000 Open source
2018-12-31	Liabilities / assets	Not reported	Total Assets: 345208000 Open source
2019-12-31	Liabilities / assets	Not reported	Total Assets: 682420000 Open source
2020-12-31	Liabilities / assets	Not reported	Total Assets: 857598000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 735016000 Open source
2022-12-31	Liabilities / assets	Not reported	Total Assets: 514491000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

6.75× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Current assets / current liabilities	1.84×	Current Assets: 106701000 Open source Current Liabilities: 58098000 Open source
20152015-12-31	Current assets / current liabilities	1.27×	Current Assets: 77259000 Open source Current Liabilities: 60820000 Open source
20162016-12-31	Current assets / current liabilities	1.46×	Current Assets: 87283000 Open source Current Liabilities: 59631000 Open source
20172017-12-31	Current assets / current liabilities	2.8×	Current Assets: 133109000 Open source Current Liabilities: 47617000 Open source
20182018-12-31	Current assets / current liabilities	6.12×	Current Assets: 342273000 Open source Current Liabilities: 55920000 Open source
20192019-12-31	Current assets / current liabilities	3.49×	Current Assets: 669276000 Open source Current Liabilities: 192014000 Open source
20202020-12-31	Current assets / current liabilities	7.11×	Current Assets: 847338000 Open source Current Liabilities: 119202000 Open source
20212021-12-31	Current assets / current liabilities	11.05×	Current Assets: 596475000 Open source Current Liabilities: 53994000 Open source
20222022-12-31	Current assets / current liabilities	6.75×	Current Assets: 397770000 Open source Current Liabilities: 58960000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	USD 689,000 Exact value Exact value: 689000 USD 2014-01-01 – 2014-12-31: 689000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REATA PHARMACEUTICALS INC · 2014-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Net Income: 689000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: 689000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459017003245/reta-20161231.xml#103754 Filing: 000156459017003245 The citation records this snapshot. The page link may show a newer release later.	−USD 88.63 million Exact value Exact value: -88630000 USD 2014-01-01 – 2014-12-31: -88630000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REATA PHARMACEUTICALS INC · 2014-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Operating Cash Flow: -88630000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -88630000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459017003245/reta-20161231.xml#127259 Filing: 000156459017003245 The citation records this snapshot. The page link may show a newer release later.	USD 183,000 Exact value Exact value: 183000 USD 2014-01-01 – 2014-12-31: 183000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REATA PHARMACEUTICALS INC · 2014-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Capital Expenditure: 183000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 183000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459017003245/reta-20161231.xml#128537 Filing: 000156459017003245 The citation records this snapshot. The page link may show a newer release later.	−USD 88.81 million Calculation and evidence -88630000 − 183000 USD Exact free cash flow: -88813000 USD 2014-01-01 – 2014-12-31: -88630000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 183000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REATA PHARMACEUTICALS INC · 2014-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Free cash flow: -88813000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -88630000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459017003245/reta-20161231.xml#127259 Filing: 000156459017003245 Input fundies:CapitalExpenditure: 183000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459017003245/reta-20161231.xml#128537 Filing: 000156459017003245 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 1.45 million Exact value Exact value: -1450000 USD 2015-01-01 – 2015-12-31: -1450000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REATA PHARMACEUTICALS INC · 2015-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Net Income: -1450000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1450000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459018004193/reta-20171231.xml#123264 Filing: 000156459018004193 The citation records this snapshot. The page link may show a newer release later.	−USD 44.62 million Exact value Exact value: -44620000 USD 2015-01-01 – 2015-12-31: -44620000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REATA PHARMACEUTICALS INC · 2015-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Operating Cash Flow: -44620000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44620000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459018004193/reta-20171231.xml#149146 Filing: 000156459018004193 The citation records this snapshot. The page link may show a newer release later.	USD 272,000 Exact value Exact value: 272000 USD 2015-01-01 – 2015-12-31: 272000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REATA PHARMACEUTICALS INC · 2015-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Capital Expenditure: 272000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 272000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459018004193/reta-20171231.xml#150423 Filing: 000156459018004193 The citation records this snapshot. The page link may show a newer release later.	−USD 44.89 million Calculation and evidence -44620000 − 272000 USD Exact free cash flow: -44892000 USD 2015-01-01 – 2015-12-31: -44620000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 272000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REATA PHARMACEUTICALS INC · 2015-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Free cash flow: -44892000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44620000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459018004193/reta-20171231.xml#149146 Filing: 000156459018004193 Input fundies:CapitalExpenditure: 272000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459018004193/reta-20171231.xml#150423 Filing: 000156459018004193 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 6.23 million Exact value Exact value: -6227000 USD 2016-01-01 – 2016-12-31: -6227000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REATA PHARMACEUTICALS INC · 2016-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Net Income: -6227000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6227000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459019005161/reta-20181231.xml#118086 Filing: 000156459019005161 The citation records this snapshot. The page link may show a newer release later.	−USD 19.26 million Exact value Exact value: -19259000 USD 2016-01-01 – 2016-12-31: -19259000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REATA PHARMACEUTICALS INC · 2016-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Operating Cash Flow: -19259000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19259000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459019005161/reta-20181231.xml#145793 Filing: 000156459019005161 The citation records this snapshot. The page link may show a newer release later.	USD 340,000 Exact value Exact value: 340000 USD 2016-01-01 – 2016-12-31: 340000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REATA PHARMACEUTICALS INC · 2016-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Capital Expenditure: 340000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 340000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459019005161/reta-20181231.xml#146827 Filing: 000156459019005161 The citation records this snapshot. The page link may show a newer release later.	−USD 19.6 million Calculation and evidence -19259000 − 340000 USD Exact free cash flow: -19599000 USD 2016-01-01 – 2016-12-31: -19259000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 340000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REATA PHARMACEUTICALS INC · 2016-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Free cash flow: -19599000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19259000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459019005161/reta-20181231.xml#145793 Filing: 000156459019005161 Input fundies:CapitalExpenditure: 340000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459019005161/reta-20181231.xml#146827 Filing: 000156459019005161 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 47.67 million Exact value Exact value: -47671000 USD 2017-01-01 – 2017-12-31: -47671000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REATA PHARMACEUTICALS INC · 2017-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Net Income: -47671000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -47671000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459020005272/reta-10k_20191231.htm#4105728 Filing: 000156459020005272 The citation records this snapshot. The page link may show a newer release later.	−USD 83.26 million Exact value Exact value: -83256000 USD 2017-01-01 – 2017-12-31: -83256000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REATA PHARMACEUTICALS INC · 2017-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Operating Cash Flow: -83256000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -83256000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459020005272/reta-10k_20191231.htm#3428894 Filing: 000156459020005272 The citation records this snapshot. The page link may show a newer release later.	USD 344,000 Exact value Exact value: 344000 USD 2017-01-01 – 2017-12-31: 344000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REATA PHARMACEUTICALS INC · 2017-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Capital Expenditure: 344000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 344000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459020005272/reta-10k_20191231.htm#3445536 Filing: 000156459020005272 The citation records this snapshot. The page link may show a newer release later.	−USD 83.6 million Calculation and evidence -83256000 − 344000 USD Exact free cash flow: -83600000 USD 2017-01-01 – 2017-12-31: -83256000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 344000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REATA PHARMACEUTICALS INC · 2017-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Free cash flow: -83600000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -83256000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459020005272/reta-10k_20191231.htm#3428894 Filing: 000156459020005272 Input fundies:CapitalExpenditure: 344000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459020005272/reta-10k_20191231.htm#3445536 Filing: 000156459020005272 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 80.55 million Exact value Exact value: -80546000 USD 2018-01-01 – 2018-12-31: -80546000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REATA PHARMACEUTICALS INC · 2018-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Net Income: -80546000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -80546000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459021009624/reta-10k_20201231.htm#4326906 Filing: 000156459021009624 The citation records this snapshot. The page link may show a newer release later.	−USD 83.78 million Exact value Exact value: -83783000 USD 2018-01-01 – 2018-12-31: -83783000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REATA PHARMACEUTICALS INC · 2018-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Operating Cash Flow: -83783000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -83783000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459021009624/reta-10k_20201231.htm#3637283 Filing: 000156459021009624 The citation records this snapshot. The page link may show a newer release later.	USD 679,000 Exact value Exact value: 679000 USD 2018-01-01 – 2018-12-31: 679000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REATA PHARMACEUTICALS INC · 2018-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Capital Expenditure: 679000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 679000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459021009624/reta-10k_20201231.htm#3648650 Filing: 000156459021009624 The citation records this snapshot. The page link may show a newer release later.	−USD 84.46 million Calculation and evidence -83783000 − 679000 USD Exact free cash flow: -84462000 USD 2018-01-01 – 2018-12-31: -83783000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 679000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REATA PHARMACEUTICALS INC · 2018-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Free cash flow: -84462000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -83783000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459021009624/reta-10k_20201231.htm#3637283 Filing: 000156459021009624 Input fundies:CapitalExpenditure: 679000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459021009624/reta-10k_20201231.htm#3648650 Filing: 000156459021009624 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 290.17 million Exact value Exact value: -290170000 USD 2019-01-01 – 2019-12-31: -290170000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REATA PHARMACEUTICALS INC · 2019-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Net Income: -290170000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -290170000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459022007338/reta-10k_20211231.htm#4049459 Filing: 000156459022007338 The citation records this snapshot. The page link may show a newer release later.	−USD 251.15 million Exact value Exact value: -251151000 USD 2019-01-01 – 2019-12-31: -251151000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REATA PHARMACEUTICALS INC · 2019-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Operating Cash Flow: -251151000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -251151000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459022007338/reta-10k_20211231.htm#3365351 Filing: 000156459022007338 The citation records this snapshot. The page link may show a newer release later.	USD 2.67 million Exact value Exact value: 2673000 USD 2019-01-01 – 2019-12-31: 2673000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REATA PHARMACEUTICALS INC · 2019-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Capital Expenditure: 2673000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2673000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459022007338/reta-10k_20211231.htm#3376447 Filing: 000156459022007338 The citation records this snapshot. The page link may show a newer release later.	−USD 253.82 million Calculation and evidence -251151000 − 2673000 USD Exact free cash flow: -253824000 USD 2019-01-01 – 2019-12-31: -251151000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2673000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REATA PHARMACEUTICALS INC · 2019-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Free cash flow: -253824000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -251151000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459022007338/reta-10k_20211231.htm#3365351 Filing: 000156459022007338 Input fundies:CapitalExpenditure: 2673000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000156459022007338/reta-10k_20211231.htm#3376447 Filing: 000156459022007338 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 247.75 million Exact value Exact value: -247752000 USD 2020-01-01 – 2020-12-31: -247752000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REATA PHARMACEUTICALS INC · 2020-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Net Income: -247752000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -247752000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#4684991 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.	−USD 322.34 million Exact value Exact value: -322340000 USD 2020-01-01 – 2020-12-31: -322340000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REATA PHARMACEUTICALS INC · 2020-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Operating Cash Flow: -322340000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -322340000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3761798 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.	USD 927,000 Exact value Exact value: 927000 USD 2020-01-01 – 2020-12-31: 927000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REATA PHARMACEUTICALS INC · 2020-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Capital Expenditure: 927000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 927000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3772997 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.	−USD 323.27 million Calculation and evidence -322340000 − 927000 USD Exact free cash flow: -323267000 USD 2020-01-01 – 2020-12-31: -322340000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 927000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REATA PHARMACEUTICALS INC · 2020-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Free cash flow: -323267000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -322340000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3761798 Filing: 000095017023004236 Input fundies:CapitalExpenditure: 927000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3772997 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 297.39 million Exact value Exact value: -297386000 USD 2021-01-01 – 2021-12-31: -297386000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REATA PHARMACEUTICALS INC · 2021-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Net Income: -297386000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -297386000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#4682735 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.	−USD 235.7 million Exact value Exact value: -235701000 USD 2021-01-01 – 2021-12-31: -235701000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REATA PHARMACEUTICALS INC · 2021-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Operating Cash Flow: -235701000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -235701000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3759594 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.	USD 1.33 million Exact value Exact value: 1329000 USD 2021-01-01 – 2021-12-31: 1329000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REATA PHARMACEUTICALS INC · 2021-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Capital Expenditure: 1329000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1329000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3770804 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.	−USD 237.03 million Calculation and evidence -235701000 − 1329000 USD Exact free cash flow: -237030000 USD 2021-01-01 – 2021-12-31: -235701000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1329000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REATA PHARMACEUTICALS INC · 2021-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Free cash flow: -237030000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -235701000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3759594 Filing: 000095017023004236 Input fundies:CapitalExpenditure: 1329000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3770804 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 311.9 million Exact value Exact value: -311901000 USD 2022-01-01 – 2022-12-31: -311901000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REATA PHARMACEUTICALS INC · 2022-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Net Income: -311901000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -311901000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#4680479 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.	−USD 204.27 million Exact value Exact value: -204267000 USD 2022-01-01 – 2022-12-31: -204267000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REATA PHARMACEUTICALS INC · 2022-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Operating Cash Flow: -204267000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -204267000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3757390 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.	USD 3.27 million Exact value Exact value: 3270000 USD 2022-01-01 – 2022-12-31: 3270000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REATA PHARMACEUTICALS INC · 2022-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Capital Expenditure: 3270000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3270000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3768611 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.	−USD 207.54 million Calculation and evidence -204267000 − 3270000 USD Exact free cash flow: -207537000 USD 2022-01-01 – 2022-12-31: -204267000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 3270000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REATA PHARMACEUTICALS INC · 2022-12-31 REATA PHARMACEUTICALS INC (edgar:1358762) Free cash flow: -207537000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:47:03Z Snapshot: e3268bef22e21f446c26437f195a975ab7285d59704228dfdf46297303902982 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358762?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -204267000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3757390 Filing: 000095017023004236 Input fundies:CapitalExpenditure: 3270000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358762/000095017023004236/reta-20221231.htm#3768611 Filing: 000095017023004236 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

47 filings · 2,033 latest values · 2,033 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001358762, 1358762, RETA, edgar:1358762

Also known as REATA PHARMACEUTICALS INC, Reata Pharmaceuticals, Inc.

REATA PHARMACEUTICALS INC

Latest quarter

Revenue

Net margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation